C12N 15/111
General methods applicable to biologically active non-coding nucleic acids
Official title: {General methods applicable to biologically active non-coding nucleic acids}
C12N15/111 (General methods applicable to biologically active non-coding nucleic acids) appears on 3,198 US grants and 7,138 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,198
- Published applications
- 7,138
- Assignees
- 1,856
- Inventors
- 10,018
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 6 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 9 |
| 2003 | 3 | 39 |
| 2004 | 2 | 96 |
| 2005 | 3 | 187 |
| 2006 | 11 | 157 |
| 2007 | 9 | 209 |
| 2008 | 10 | 204 |
| 2009 | 64 | 249 |
| 2010 | 104 | 271 |
| 2011 | 108 | 280 |
| 2012 | 155 | 259 |
| 2013 | 156 | 243 |
| 2014 | 180 | 254 |
| 2015 | 175 | 306 |
| 2016 | 176 | 297 |
| 2017 | 226 | 281 |
| 2018 | 218 | 368 |
| 2019 | 219 | 375 |
| 2020 | 211 | 329 |
| 2021 | 193 | 418 |
| 2022 | 187 | 477 |
| 2023 | 225 | 405 |
| 2024 | 189 | 486 |
| 2025 | 211 | 574 |
| 2026 | 145 | 365 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- AAV delivery of nucleobase editors29 Sep 2026US 12,746,294 B2President and Fellows of Harvard College
- Modulation of expression of genes related to T cell exhaustion29 Sep 2026US 12,747,431 B2The Trustees of the University of Pennsylvania
- Multiplex RNA-guided genome engineering29 Sep 2026US 12,747,456 B2President and Fellows of Harvard College
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Transcription factor 4 gene editing system8 Oct 2026US 2026/0306671 A1The Regents of the University of California
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
- Novel regulatory cassettes for specific expression of genes in muscle stem cells8 Oct 2026US 2026/0306674 A1University of Washington
- Epigenetic repression protein therapy for rasopathies8 Oct 2026US 2026/0306675 A1Battelle Memorial Institute
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- CRISPR-Cas systems and methods for altering expression of gene products483US 8,945,839 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas systems and methods for altering expression of gene products470US 8,771,945 B1Massachusetts Institute of Technology · 2014
- RNA interference mediating small RNA molecules382US 7,056,704 B2MAX-PLANCK-GESELLSCHAFT zur FOERDERUNG der WISSENSCHAFTEN.e.V · 2006
- Cationic lipids and methods for the delivery of therapeutic agents380US 8,569,256 B2Protiva Biotherapeutics, Inc. · 2013